Browsing Category
Pharma Industry News
4747 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Firebrick Pharma (ASX:FRE) surges as Nasodine Phase 3 trial confirms 40% cold relief
Firebrick Pharma’s Phase 3 Nasodine trial confirms 40% symptom relief in cold patients. Discover how this could accelerate global sales and investor interest.
Merck (NASDAQ: MRK) wins FDA approval for ENFLONSIA to prevent RSV in infants
FDA clears Merck’s ENFLONSIA (NASDAQ: MRK) for RSV prevention in infants. See trial data, stock reaction, pediatric market impact & analyst projections.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.
Merck’s enlicitide shows major LDL-C reduction in Phase 3 trials, raising hopes for first oral PCSK9 approval
Merck’s enlicitide hits key milestones in Phase 3 trials, bringing the first oral PCSK9 inhibitor closer to market. Will this reshape LDL-C treatment?
Samsung Bioepis-NIPRO alliance boosts biosimilar pipeline in Japan’s $1.4B market
Samsung Bioepis (KRX: 207940) and NIPRO’s biosimilar partnership expands Japan market access amid rising healthcare costs and global biologics competition.
Dishman Carbogen Amcis (NSE: DCAL) to expand ADC manufacturing in Switzerland
Dishman Carbogen Amcis expands Swiss ADC manufacturing with CHF 25M co-investment. Learn how this aligns with its global CDMO strategy.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Scinai Immunotherapeutics secures Italian approval to advance Pincell acquisition and PC111 development
Scinai Immunotherapeutics receives Italian Golden Power clearance for proposed Pincell buyout, moving closer to advancing PC111 monoclonal antibody program.
Vepdegestrant delivers Phase 3 success for Arvinas and Pfizer in ESR1-mutant breast cancer
Vepdegestrant shows 43% risk reduction in ESR1-mutant breast cancer vs fulvestrant. Learn how Arvinas and Pfizer aim for FDA filing in H2 2025.
Allay Therapeutics raises $57.5m to advance ATX101 non-opioid pain therapy in knee surgery
Allay Therapeutics raises $57.5M to advance ATX101 pain therapy in U.S. knee surgery trial, with FDA backing and growing Asia partnerships.